Cart
sales@molnova.com
Sweroside
CAS No. 14215-86-2
Sweroside( —— )
Catalog No. M18009 CAS No. 14215-86-2
Sweroside is a promising osteoporosis therapeutic natural product, has anti-osteoporotic effect on the human MG-63 cells and rat osteoblasts.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 37 | In Stock |
|
| 2MG | 29 | In Stock |
|
| 5MG | 48 | In Stock |
|
| 10MG | 67 | In Stock |
|
| 25MG | 107 | In Stock |
|
| 50MG | 152 | In Stock |
|
| 100MG | 222 | In Stock |
|
| 200MG | 331 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSweroside
-
NoteResearch use only, not for human use.
-
Brief DescriptionSweroside is a promising osteoporosis therapeutic natural product, has anti-osteoporotic effect on the human MG-63 cells and rat osteoblasts.
-
DescriptionSweroside possesses strong hepatoprotective effect. Sweroside is a promising osteoporosis therapeutic natural product, has anti-osteoporotic effect on the human MG-63 cells and rat osteoblasts.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number14215-86-2
-
Formula Weight358.34
-
Molecular FormulaC16H22O9
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (279.06 mM)
-
SMILESC=CC1C2CCOC(=O)C2=COC1OC3C(C(C(C(O3)CO)O)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PF-06651600
PF-06651600 is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2; inhibits Th1 and Th17 cell differentiation and function, reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models; selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β production in IL-27-primed macrophages.Rheumatoid ArthritisPhase 2 Clinical
-
Londamocitinib
Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.
-
CYT387
A potent and selective JAK1/JAK2 inhibitor with IC50 of 11/18 nM.
